Volume 26, Number 12—December 2020
Dispatch
Hypervirulent Klebsiella pneumoniae as Unexpected Cause of Fatal Outbreak in Captive Marmosets, Brazil
Table 2
Antimicrobial susceptibility profile of highly virulent Klebsiella pneumoniae sequence type 86 strain P04 from a fatal epizootic among captive marmosets in Brazil, 2019*
Antimicrobial | MIC, mg/L† | Category |
---|---|---|
Amikacin | <4.0 | Susceptible |
Ampicillin/sulbactam | 8/4 | Susceptible |
Aztreonam | <2 | Susceptible |
Cefepime | <2 | Susceptible |
Cefotaxime | <2 | Susceptible |
Ceftazidime | <1.0 | Susceptible |
Ciprofloxacin | <0.06 | Susceptible |
Colistin | <0.25 | Susceptible |
Doripenem | <0.5 | Susceptible |
Doxycycline | 2.0 | Susceptible |
Gentamicin | <1.0 | Susceptible |
Imipenem | <1.0 | Susceptible |
Levofloxacin | <1.0 | Susceptible |
Meropenem | <1.0 | Susceptible |
Minocycline | 4.0 | Susceptible |
Piperacillin/tazobactam | <8/4 | Susceptible |
Polymyxin B | <0.25 | Susceptible |
Sulfamethoxazole/trimethoprim | <0.5/9.5 | Susceptible |
Ticarcillin/clavulanic Acid | <16/2 | Susceptible |
Tigecycline‡ | 0.5 | Susceptible |
Tobramycin | <1.0 | Susceptible |
*Susceptibility determined by Sensititre (ThermoFisher, https://www.thermofisher.com). †MIC values were categorized as susceptible, intermediate, or resistance following Clinical and Laboratory Standards Institute (https://clsi.org) M100-S30 breakpoints (http://em100.edaptivedocs.net/dashboard.aspx). ‡Tigecycline breakpoint followed Food and Drug Administration recommendations.